Colleen Wilson’s Post

Today is an exciting day of firsts for Strand Therapeutics. We are proud to announce the dosing of our first patient with STX-001 in our first Phase 1 trial for the treatment of cancer patients with solid tumors. STX-001 represents the first-ever programmable mRNA therapy to enter clinical trials. STX-001 is an investigational multi-mechanistic, synthetic self-replicating mRNA technology that expresses an IL-12 cytokine for an extended duration, directly into the tumor microenvironment. Join us at ASCO for more information on the trial design: Presentation Date/Time: 6/1/2024 9:00AM-12:00PM CDT Title: A phase I trial of intratumoral STX-001: A novel self-replicating mRNA expressing IL-12 alone or with pembrolizumab in advanced solid tumors. Session: Developmental Therapeutics -- Immunotherapy Location: McCormick Place, Chicago, Illinois, Hall A Poster Board Number: 161b Permanent Abstract Number: TPS2696 Read our press release: https://lnkd.in/g-j9vq6v #Programmable #mRNA #Oncology #ClinicalTrials #FirstPatientDosed #ASCO24 #ASCO2024

Exciting news to share today

Today is a monumental day for Strand Therapeutics! We are beyond thrilled to announce that we have dosed our first patient with STX-001 in the company's first clinical trial! This groundbreaking therapy promises to induce deep anti-tumor immune responses and prevent cancer recurrence with minimal systemic exposure of the drug in solid tumor patients. A heartfelt thank you to the patients signing up for this trial - your fight against cancer is our inspiration. A huge shoutout to our incredible world renowned investigators for running this trial and to every single Strand employee - from discovery, preclinical, manufacturing, clinical, G&A, and to our advisors - your dedication made this possible. Gratitude also goes out to our investors and partners for believing in our vision, and to the funding agencies and academic collaborators who supported our research journey from MIT to Strand. For me, this journey began 12 years ago when I first started programming mRNA in the lab, and today, seeing it administered to our first patient is nothing short of a dream come true. This is just the beginning, and I can’t wait to see the positive impact we will make on countless lives. Let’s transform patient care together! Join us at ASCO for more insights on our trial design and the future of cancer therapy. Presentation Date/Time: 6/1/2024 9:00AM-12:00PM CDT Location: McCormick Place, Chicago, Illinois, Hall A Poster Board Number: 161b Permanent Abstract Number: TPS2696 Read our press release: https://lnkd.in/g-j9vq6v #Programmable #mRNA #Oncology #ClinicalTrials #FirstPatientDosed #ASCO24 #ASCO2024

A total of nearly 70 poster abstracts were submitted to the Chinese Antibody Society 2023 conference. Three of them were selected as oral presentations and an additional 20 of these abstracts were selected and presented as posters at the conference. Finally, 25 abstracts were selected and published in our society’s official journal, Antibody Therapeutics (2022 CiteScore: 6.4). We will be sharing them here one by one with our society’s LinkedIn account.  The 8th poster is from Chengbin Wu at EpimAb Biotherapeutics, Inc. entitled ‘A NOVEL IMMUNOSTIMULATORY PD-L1/OX40 TETRAVALENT BISPECIFIC ANTIBODY FOR CANCER IMMUNOTHERAPY’. Bispecific antibodies (BsAb) combining PD-L1 blockade and OX40 co-stimulation have shown promise in cancer therapy. As per the abstract, EMB-09, a novel Fc-silenced tetravalent PD-L1/OX40 BsAb, demonstrated enhanced anti-tumor activity, synergy in T-cell activation, and favorable safety profiles in preclinical studies.     Follow the Chinese Antibody Society for the latest research in antibody therapeutics. Access the full abstract at: https://lnkd.in/gKY6J9xX #antibody #antibodies #bispecific #antibodytherapeutics #antibodyengineering #biologics #poster

GenFleet Therapeutics announced China's National Medical Products Administration (NMPA) has approved the clinical trial application for GFH375 (VS-7375) in an open-label, multi-center phase I/II study targeting advanced solid tumor patients with KRAS G12D mutation. G12D mutation is the most prevalent KRAS mutation detected in human cancers, and no G12D-targeted therapies have been approved yet. GFH375 is a highly potent and selective KRAS G12D inhibitor targeting both "ON" (GTP-bound) and "OFF" (GDP-bound) states of the protein. According to the latest preclinical findings posted at 2024 AACR annual meeting, GFH375 demonstrated preliminary safety data, favorable oral bioavailability and potent efficacy across preclinical models; moreover, GFH375 holds the potential for treating G12D-mutant cancers with brain metastases. Please click the link for its full version: https://lnkd.in/gYS7mVHu Find out more at GenFleet's official website: http://www.genfleet.com/en #biotech #cancer therapeutics #immunology

Did you know that pre-treated PDX tumor models offer exclusive insights into drug resistance mechanisms in cancer therapy? Dive into Champions' latest blog to explore how our expansive, highly characterized biobank of pre-treated PDX models helps researchers devise superior strategies to overcome drug resistance. With a repository of over 1,000 pre-treated tumor models sourced from 60+ tumor types, Champions' PDX biobank offers researchers an unparalleled resource. Our pre-treated models offer a unique platform to probe resistance mechanisms in models closely mimicking the molecular and cellular characteristics of the original patient tumors. Key features of Champions' PDX biobank include: ✅Models derived from advanced-stage primary and metastatic tumors, representing diverse tumor stages. ✅Pre-treated models with a range of therapies, enabling comprehensive exploration of resistance mechanisms. ✅Accessible through Lumin for precise model selection based on clinical characteristics, facilitating tailored studies. ✅Ideal for evaluating therapeutics in a setting that mirrors the real-world patient population, thus mitigating drug development risks. Explore our blog to uncover how these models can accelerate the development of your advanced cancer treatments, bringing better cancer treatments to patients worldwide. #CancerResearch #DrugDiscovery #PDXModels #Oncology #TumorModels https://hubs.li/Q02tn0Wc0

We’re counting down the days until #ASCO24 begins! GeneCentric will have a poster presentation that includes new clinical validation results for a novel signature identifying patients with head and neck squamous cell carcinoma (HNSCC) who may benefit from treatment beyond typical surgical resection. We’ll also present updated findings from our development of a novel RNA-based immune checkpoint inhibition predictive response signature that optimizes the selection of patients with a primary diagnosis of urothelial cancer who are potential candidates for anti-PD-(L)1 inhibition treatment. Details at https://bit.ly/4bnESvX American Society of Clinical Oncology (ASCO) The University of Tennessee Health Science Center University of Pittsburgh School of Medicine #oncology #biotechnology #pharmaceuticals #RNAseq

We're thrilled to announce the clearance of an Investigational New Drug (IND) application for our groundbreaking programmable mRNA therapy, STX-001, designed to treat solid tumors. 🎉 This marks a significant milestone as we move forward to initiate a Phase 1, first-in-human trial with the U.S. FDA. STX-001 is a multi-modal synthetic self-replicating mRNA technology, delivering a prolonged and locally-acting IL-12 cytokine to the tumor microenvironment. 🧬 Our CEO & Co-Founder, Jacob Becraft, believes STX-001 has the potential to become the first programmable mRNA therapy in oncology. 🌐 We're excited about the prospects of advancing our program into human clinical trials and exploring the vast therapeutic potential across different areas. Stay tuned for updates as we continue to push the boundaries in the field of programmable mRNA therapeutics! Read our press release: https://lnkd.in/eV2EwZ6C #Programmable #mRNA #Oncology #ClinicalTrials #LogicCircuits

Progress in the fields of chemistry, pharmacology, and immunology has led to the advancement of Antibody-Drug Conjugates (ADCs), which exhibit significant clinical effectiveness in specific subsets of lung cancer patients. ADCs are being investigated for targets like TROP-2, HER2, HER3, MET, and CEACAM5, both as standalone treatments and in combination with other therapies. Although ADCs are gaining ground in clinical practice, understanding resistance mechanisms is crucial for future development, although such data remains limited due to the early stage of ADC research in lung cancer. Prominent companies like Daiichi Sankyo, Inc., AstraZeneca, Gilead Sciences, Sanofi, AbbVie, and several others are actively engaged in the field of Antibody-Drug Conjugates (ADCs) therapeutics. Get more detailed insights, at: https://lnkd.in/ddB5if7g #healthcare #biotechnology #lifesciences #market #marketforecast #marketanalysis #fda #healthcaremarket #healthcareindustry #marketoutlook #antibodydrugconjugates #ADC

phase 2 umbrella HUDSON study evaluated rational combination regimens for advanced NSCLC following failure of anti-PD-(L)1-containing immunotherapy and platinum-doublet therapy. A total of 268 patients received durvalumab (anti-PD-L1 monoclonal antibody)–ceralasertib (ATR kinase inhibitor), durvalumab–olaparib (PARP inhibitor), durvalumab–danvatirsen (STAT3 antisense oligonucleotide) or durvalumab–oleclumab (anti-CD73 monoclonal antibody). Biomarker directed #Biomarkerdirectedtrial #Biomarkerinoncology #Oncology #Innovation #Clinicaldevelopment #Medicalaffairs